Larkin Finbar's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Mar 7, 2023
- Accession no.
- 0001765581-23-000032
- Filed
- Mar 7, 2023
- Trade date
- Mar 3-7, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $537.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Larkin FinbarCIK 0001793243 | Officer (SVP, Technical Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2023 | Ordinary Shares | AGrant or awardAcquired | +4,373 | $0.00 | $0 | 23,854 | Direct | |
| Mar 6, 2023 | Ordinary Shares | MOption exerciseAcquired | +1,706 | $58.72 | +$100,176.32 | 25,560 | Direct | |
| Mar 6, 2023 | Ordinary Shares | SSaleDisposed | −1,706 | $143.92 | −$245,527.52 | 23,854 | Direct | |
| Mar 7, 2023 | Ordinary Shares | SSaleDisposed | −2,075 | $140.76F4 | −$292,077 | 21,779 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2023 | Ordinary Shares | MOption exerciseDisposed | −1,706 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $140.7578 to $140.7656 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.